Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study

• Prif Awduron: Bernhard Korge (Awdur), Olivier Vanhooteghem (Awdur), Charles W. Lynde (Awdur), Alena Machovcova (Awdur), Marc Perrussel (Awdur), Elisavet Lazaridou (Awdur), Claudio Marasca (Awdur), David Vidal Sarro (Awdur), Ines Duenas Pousa (Awdur), Frederik Fierens (Awdur), Paulette Williams (Awdur), Saori Shimizu (Awdur), Tanja Heidbrede (Awdur), Richard B. Warren (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Adis, Springer Healthcare, 2024-06-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Abstract Introduction Certolizumab pegol (CZP) is an anti-tumor necrosis factor alpha (TNFα) approved for the treatment of moderate to severe plaque psoriasis (PSO). However, data on its real-world use is currently limited. The objective of this study was to describe the 1-year real-world effectiven...